Ad
related to: treatment options for nash mean cancer marker levels interpretation
Search results
Results from the WOW.Com Content Network
The level of tumor marker should indicate the state of the malignancy to be able to monitor treatment response. An ideal tumor marker does not exist, and how they are clinically applied depends on the specific tumor marker. For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give ...
Levels or presence of biomarker should readily distinguish between normal, cancerous, and precancerous tissue; Effective treatment of the cancer should change the level of the biomarker; Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer
Progressive disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Evaluation of non-target lesions. Complete response (CR): Disappearance of all non-target lesions and normalization of tumor marker level
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention."
In biomedical contexts, a biomarker, or biological marker, is a measurable indicator of some biological state or condition. Biomarkers are often measured and evaluated using blood, urine, or soft tissues [ 1 ] to examine normal biological processes , pathogenic processes, or pharmacologic responses to a therapeutic intervention . [ 2 ]
Grading in cancer is distinguished from staging, which is a measure of the extent to which the cancer has spread. Pathology grading systems classify the microscopic cell appearance abnormality and deviations in their rate of growth with the goal of predicting developments at tissue level (see also the 4 major histological changes in dysplasia).
While many treatments appear to improve biochemical markers such as alanine transaminase levels, most do not reverse histological abnormalities or improve outcomes. [ 5 ] [ 14 ] [ 103 ] [ needs update ] Treatment with medications is primarily aimed at improving liver disease and is generally limited to those with biopsy-proven NASH and fibrosis.
Cancer staging can be divided into a clinical stage and a pathologic stage. In the TNM (Tumor, Node, Metastasis) system, clinical stage and pathologic stage are denoted by a small "c" or "p" before the stage (e.g., cT3N1M0 or pT2N0). This staging system is used for most forms of cancer, except brain tumors and hematological malignancies.
Ad
related to: treatment options for nash mean cancer marker levels interpretation